Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

trial for ANA773 in cancer patients in February and this study of ANA598 underway, Anadys is now focused on achieving important clinical milestones in both programs."

About ANA598

ANA598 is a highly potent and selective inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases (IC50 < 1 nM) and of HCV replication in cell culture (EC50 values for genotypes 1b and 1a replicons are 3 and 50 nM, respectively). ANA598 has been well-tolerated in all preclinical studies, including 28-day GLP toxicology studies, and was selected as a development candidate in June 2007.

Clinical Need and Market Opportunity in HCV Infection

Chronic hepatitis C virus (HCV) infection is a serious public health concern affecting approximately 2.7 million people in the United States and approximately 170 million people worldwide. HCV causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer, and ultimately, liver failure. Cirrhosis of the liver resulting from chronic HCV infection is the leading indication for liver transplantation in the U.S. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the U.S. die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy, support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the U.S. are under treatment today. The majority of infected individuals are unaware of their infection status and the large majority of individuals who know their status do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) ... to Prepare Application Dossiers for Oversea Medical device ... report to their offering. The ... market of the most growth potentiality, which is ... and producers to penetrate such market. It is ...
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... Partners, Aesculap and Tornier, Conduct Clinical ... Evaluations of TephaFLEX(R) Suture Products, LEXINGTON, Mass., ... derived from a new class of polymers, announced today ... conducting initial,clinical evaluations of the Company,s new TephaFLEX(R) suture ...
... (Nasdaq: KOSN ) presented preclinical data on ... vitro and in vivo,activity as well as tolerability ... anticancer mechanism of action correlating inhibition,of the target ... cells,compared to normal cells. Data on Kosan,s NEIs ...
Cached Medicine Technology:Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:5/24/2015)... 2015 Indiana Fiber Network, LLC (IFN), ... Telecom of America, Inc. (MTA) has selected IFN as ... Childs, IFN Enterprise Sales Manager, fiber route diversity and ... fiber transport provides MTA with the diverse fiber transport ... 1 Internet and voice carriers located at Henry Street ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 ... System CEO - The students ... honored at the fourth annual A ... 15 at Geneva National in Lake ... ,     -Badger High School,         Jonathan Alfonso, ...
(Date:5/23/2015)... May 23, 2015 On Saturday, May 23, ... new playground for Branches Florida City exactly five years to ... space in 2010. , A large fire tore through the ... May 23, 2010 in the middle of the night as ... was later declared arson even though it is suspected that ...
(Date:5/23/2015)... 2015 Dr. David Benvenuti, an experienced plastic ... a new article to his website that takes ... Benvenuti explained in the fascinating blog, he has recently ... earlobes. , Known as “gauging,” the technique involves placing larger ... Benvenuti said will eventually stretch the holes out to incredible ...
(Date:5/23/2015)... 2015 On Wednesday, May 20, 2015, ... has been the target of a sophisticated cyberattack,” and ... company’s ongoing Information Technology (IT) security efforts in the ... The most notable attack on health insurers was reported ... nation’s second largest health insurer, revealed that they had ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... of Allergy and Infectious Diseases (NIAID), part of the ... to two programs that support research to better understand ... diseases, including those that may be introduced into a ... awarded to the Cooperative Centers for Translational Research on ...
... parents around the country are starting to face school ... for a school to shut down? A study led ... PhD of the Children,s Hospital Boston Informatics Program, in ... (Niigata, Japan), tapped a detailed set of Japanese data ...
... ... Change , ... D.C. (Vocus) November 4, 2009 -- Changes to the Earth’s land cover, climate, and ... and now represent the greatest public health challenge of the 21st century. The scale ...
... half of those with lung disease symptoms remain undiagnosed, experts ... Americans are aware of chronic obstructive pulmonary disease (COPD), but ... be treated, according to national survey results released this week ... Month in November. , COPD affects 20 percent of U.S. ...
... , ... Future-focused performance management system prepares hospital leaders for the changing health care environment. ... ... extreme financial challenges—payment reform, reimbursement changes and a shift of patient services to ...
... 4 In order to help millions of ... medical conditions, depression and obesity, the Neutraceutical Company, ... with the ability to address both issues safely ... Wellness brand, has clinically established a remarkable success ...
Cached Medicine News:Health News:NIAID announces new human immunology research awards to help fight emerging infectious diseases 2Health News:NIAID announces new human immunology research awards to help fight emerging infectious diseases 3Health News:When should flu trigger a school shutdown? 2Health News:When should flu trigger a school shutdown? 3Health News:Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health 2Health News:Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health 3Health News:Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health 4Health News:Americans Gaining Awareness of COPD: Survey 2Health News:Sg2 Announces Its INSIGHT System to Improve Hospitals' Clinical Performance and Bottom Line Results 2Health News:Sg2 Announces Its INSIGHT System to Improve Hospitals' Clinical Performance and Bottom Line Results 3Health News:New Product Launch - SAFFRENE Delivers Impressive Mood Elevation and Weight-loss Benefits 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: